Endoscopic Device Biocompatible Materials Patents: Leaders, Trends & White Space 2026
- Filing has cooled since its 2021 peak. 32 families filed that year against 20 in 2017, but the trend has since flattened toward single-digit annual counts, suggesting the core coating and insertion-tube claim space is filling in rather than expanding.
- Claims cluster hard around A61B and A61M. 422 of 434 families touch diagnosis-and-surgery classifications and 126 touch body-fluid devices, while optics, sterilising chemistry and software-adjacent classes each carry a fraction of that volume.
- The US is the dominant filing venue by a wide margin. 215 records were filed at the US receiving office against 74 at the EPO and 52 via WIPO, so freedom-to-operate work for this technology has to start with US prior art.
What this landscape covers
This dataset tracks patent families addressing endoscope and endoscopic device claims that specifically touch biocompatible coating, lubricious coating, insertion tube material, or sterilizable material language, filtered against IPC classes covering diagnosis and surgery instruments and biocompatible/absorbable material chemistry. The intersection is deliberately narrow: it excludes general endoscope mechanics that never engage a material or coating claim, and it excludes general biomaterials work that never anchors to an endoscopic device.
Coverage runs from 2015 through the mid-2026 data cut-off. Because publication typically lags filing by around eighteen months, the last one to two years in any trend line will always look thinner than they will eventually turn out to be once pending applications publish.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
434 patent families sit inside this search, spread across a decade of filing activity and eight overlapping IPC subclasses. The shape of both tells you where the claim space is dense and where it is thin.
A peak in 2021, then a pullback
Annual filings rose from 20 in 2017 to a peak of 32 in 2021, sat at 8 by the 2022 midpoint, and have continued to decline into the low single digits through the most recent recorded year — read the final year or two as undercounted given publication lag, but the multi-year direction is down, not up.
Concentration in A61B and A61M
A61B (diagnosis and surgery) appears in 422 of 434 records and A61M (body fluid devices) in 126, confirming that most claims are anchored to the physical endoscope or catheter assembly rather than to the coating chemistry itself. G02B (optics, 51), A61L (sterilising and disinfecting, 30), and the informatics-adjacent G16Z/G16H classes (26 and 24) show that imaging, sterilisation and software integration are present but secondary threads, while A61F (implants, 11) is a minor overlap.
Shares are the percentage of the 434 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Endoscopic Device Biocompatible Materials with Eureka
This page is one run against one query. Ask Eureka your own question about endoscopic device biocompatible materials and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited prior art in this space
Endoscopic device with additional channel
An endoscopic device is described and includes at least an endoscope and one or more catheters, and a means for securing the endoscope to the catheter at a distal end of the endoscopic device. The means for securing the endoscope may be a sleeve or distal cap. The sleeve includes at least a first opening for securing the catheter therebetween and a second opening for securing the endoscope adjacent to the catheter.Filed by United States Endoscopy Group; published 2022-05-26.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6179776B1 | Controllable endoscopic sheath apparatus and related method of use | 1,983 |
| 2 | US6761685B2 | Controllable endoscopic sheath apparatus and related method of use | 1,752 |
| 3 | US6835173B2 | Robotic endoscope | 1,568 |
| 4 | US6770027B2 | Robotic endoscope with wireless interface | 1,542 |
| 5 | US7070559B2 | Controllable endoscopic sheath apparatus and related method of use | 1,529 |
| 6 | US7591783B2 | Articulation joint for video endoscope | 1,506 |
| 7 | US9829698B2 | Endoscope | 1,009 |
| 8 | US9763741B2 | System for robotic-assisted endolumenal surgery and related methods | 953 |
| 9 | WO2000054653A1 | Controllable endoscopic sheath | 875 |
| 10 | US5997517A | Bonding layers for medical device surface coatings | 576 |
Citation counts reflect influence inside this searched corpus and skew toward older filings; they are not a measure of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns stand out once the trend and classification data are read together: a maturing core, a small but real venue concentration, and a citation record dominated by a handful of very old sheath and robotic-endoscope patents.
Growth has already flattened
The climb from 20 filings in 2017 to 32 in 2021 looked like an expanding field. The drop to 8 by the 2022 midpoint and lower since indicates the accessible claim territory around coatings and insertion-tube materials is largely staked out, not still opening up.
US filings dominate the venue mix
With 215 records at the US office against 74 at the EPO, 52 via WIPO and smaller counts in Canada, Australia and Austria, most enforceable rights in this space sit under US examination practice, which shapes how narrowly material and coating claims tend to be drafted.
Citation weight sits in early sheath patents
The most-cited records in this corpus are controllable sheath and robotic-endoscope patents from an earlier generation of filings, each carrying well over a thousand citations. That weight reflects foundational status, not that these are the claims most likely to be asserted against a new material or coating today.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to endoscopic device biocompatible materials, with the prior art for and against each one.
Who is filing, and how much runway is left
Assignee activity in the most recent year is thin across the board, which is consistent with a field that has passed its filing peak rather than one still building momentum behind a handful of leaders.
Boston Scientific International leads a quiet field
Boston Scientific International shows the only recorded filing in the latest year among the tracked assignees, and even that is flat year-on-year. No assignee in this dataset is currently scaling filings.
Collaboration is limited and inventor-linked
Co-filing pairs top out at three shared families, mostly pairing a corporate assignee with a named inventor rather than two companies jointly filing. This points to internal R&D partnerships rather than cross-company joint ventures.
A long tail of narrow-scope filers
Beyond the handful of assignees with multiple families, the ranking includes academic and specialty-device entities such as Cornell University and Lumendi, each holding a small, focused slice of claim territory rather than broad platform coverage.
| Assignee | Recent year | YoY |
|---|---|---|
| Boston Scientific International | 1 | 0% |
| Boston Scientific Limited (UK) | 0 | — |
| Lumendi | 0 | — |
| Cornell University | 0 | — |
| Scientia Medica Life Systems, Inc. | 0 | — |
| Panasonic Corporation (Japan) | 0 | — |
| Micro Vention, Inc. | 0 | — |
| Auris Surgical Robotics | 0 | — |
Where to take this analysis
The classification and trend data point to where claim density is heavy and where it is thin, but a filing or freedom-to-operate decision needs the underlying claim language, not just the counts.
Map the coating chemistry sub-claims
Pull full claim sets for the A61L-tagged sterilising and disinfecting families to see exactly which lubricious or antimicrobial chemistries are already locked up versus described only in passing.
Explore coating claims in EurekaCheck the optics and informatics overlaps
G02B and G16H overlaps are small in count but could hide blocking claims for any device that combines a biocompatible coating with imaging or sterilisation-tracking software.
Search the overlap claims in EurekaCommon questions on this landscape
This dataset tracks 434 patent families published between 2015 and the mid-2026 data cut-off that combine endoscope or endoscopic device claims with biocompatible coating, lubricious coating, insertion tube material, or sterilizable material language. It is a narrow intersection filter, so the true universe of endoscope-adjacent material patents is larger; this count reflects only families where the material or coating claim is explicit. Treat 434 as the addressable core rather than the full biomaterials-in-endoscopy market.
No. Filings rose from 20 in 2017 to a peak of 32 in 2021, then dropped to 8 by the 2022 midpoint and have stayed in single digits since. The most recent one to two years are understated because publication lags filing by roughly eighteen months, but the multi-year trend is clearly a pullback from the 2021 peak rather than continued growth. That pattern usually means the obvious claim territory is already occupied.
The United States is by far the largest venue, with 215 of 434 records filed there, followed by the European Patent Office at 74 and the WIPO/PCT route at 52. Canada, Australia and Austria each carry smaller but non-trivial shares. Any clearance search should start with US prior art and then check EPO and PCT filings for corresponding family members before assuming a US-only search is sufficient.
US20220160213A1, assigned to United States Endoscopy Group and published 2022-05-26, describes an endoscopic device with an endoscope, one or more catheters, and a means for securing the endoscope to the catheter using a sleeve or distal cap with two openings. The claim scope centers on the mechanical securing structure at the distal end rather than on a novel coating or bulk material chemistry. Anyone designing a similar multi-channel securing sleeve should review this filing's exact claim boundaries before finalizing a device architecture.
The classification data shows heavy concentration in A61B and A61M device claims but comparatively light activity in the optics overlap (G02B, 51 records), sterilising chemistry specifically (A61L, 30 records) and informatics-linked sterilisation tracking (G16H, 24 records). Sub-areas such as antimicrobial insertion-tube polymer blends, sterilizable lubricious hydrogels, and absorbable distal-cap materials show lower record density than the core mechanical claims. These are reasonable starting points for a novelty search, though low counts should be confirmed against full claim text before assuming the space is truly open.
Research Endoscopic Device Biocompatible Materials in depth with Eureka
Go past this page: query the whole endoscopic device biocompatible materials corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.